A Phase 2 interventional study of Vancomycin hydrochloride inhalation powder and Placebo inhalation powder in Cystic Fibrosis, sponsored by Savara Inc.. Completed at 38 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-01-13.
Sponsored by Savara Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 717 studies in Cystic Fibrosis with a site in United States — 86 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.
Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 136th largest by enrollment of the 517 interventional ones that give a count, is one of 37 that started in 2013, is one of 103 in phase 2, and was the 265th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →86 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 3–18
Ghady Haidar · Sites in United States
Ages 18+
Anagram Therapeutics, Inc. · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
717 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 143 · Phase 3 108 · Phase 4 47
First in 1988; this study’s year is marked. 37 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 36 across the 517 interventional studies, 80 across the 193 observational. Of the 569 that completed or were terminated, 263 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
250 of 717 have an industry lead sponsor. The 10 most frequent:
Savara Inc. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Savara Inc. has 5 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
43 of the studies in Cystic Fibrosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413368Phase 3Children's Hospital Los AngelesMaralixibat in Patients With Cystic Fibrosis and Constipation | 2027-06-30 |
| NCT06449677Phase 3Jaeb Center for Health ResearchBionic Pancreas in CFRD | 2027-06-30 |
| NCT06996951Phase 3Indiana UniversitySinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | 2027-07 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 717 studies in Cystic Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether AeroVanc treatment is safe and effective in reducing the number of MRSA colony forming units in the lungs of cystic fibrosis patients.
This is a Phase 2a randomized, multicenter, double-blind, placebo-controlled, parallel group study to examine the safety and efficacy of AeroVanc in the treatment of persistent MRSA lung infection in CF patients. Pharmacokinetics will be evaluated in a subgroup by measuring plasma and sputum concentrations of vancomycin.
Prior to treatment, patients will be randomized to receive either AeroVanc twice daily (bid), or placebo bid. Patients will be stratified based on the presence of a Pseudomonas aeruginosa (P. aeruginosa) co-infection that is being treated with a chronic suppression regimen. Patients with P. aeruginosa co-infection can be on any chronic inhaled suppression regimen (or nothing if the patient is considered stable in the opinion of the investigator despite the lack of treatment). Regardless of treatment regimen, if there is an off month, screening should be scheduled so that AeroVanc or placebo administration can be given during this time. Patients with no off month should be screened so that the AeroVanc or placebo administration period coincides with a treatment cycle other than TOBI (e.g., Cayston or colistin). All patients must have at least a 24-hour washout period after stopping their anti-Pseudomonas therapy and prior to the Visit 2 (Baseline) pre-dose microbiology sputum sample. The AeroVanc or placebo treatment duration is 28 days, during which efficacy and safety parameters will be measured, and after which patients will be followed up for 56 days.
There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evidence, defined as one or both of the following, that the persistent MRSA lung infection is suspected to be causing health consequences.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
32 or 64 mg twice daily (BID)
Drug: Vancomycin hydrochloride inhalation powder
Matching placebo inhalation powder BID
Drug: Placebo inhalation powder
There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.
Also known as: AeroVanc
Change From Baseline in MRSA Sputum Density.
Change from Baseline at Day 29 of the dosing period (start of AeroVanc/Placebo administration is considered Day 1 of the dosing period) in the number of MRSA colony forming units (CFU) in sputum culture.
Time frame: Day 29 of treatment period
Change From Baseline in MRSA Sputum Density.
Time frame: Day 8 of treatment period
Change From Baseline in MRSA Sputum Density.
Time frame: Day 15 of treatment period
Change From Baseline in FEV1
Absolute change from baseline in FEV1 percent predicted
Time frame: Day 29 of treatment period
Change From Baseline in FVC
Absolute change from baseline in FVC percent predicted
Time frame: Day 29 of treatment period
Change From Baseline in Cystic Fibrosis Respiratory Symptom Diary (CFRSD-CRISS) Scores
Change from Baseline in Cystic Fibrosis Respiratory Symptom Diary (CFRSD) Chronic Respiratory Infection Symptom Scores (CRISS). The minimum score is 0 and the maximum is 100, where a higher score means a worse outcome.
Time frame: Day 29 of treatment period
Time From Start of Dosing to First Administration of Other Antimicrobial Medications (Oral, Intravenous and/or Inhaled) Due to Respiratory Symptoms.
Time frame: Entire study: Day 1 of treatment period through 8 week post-treatment follow up visit
Time From Start of Dosing to Exacerbation of Signs/Symptoms (Fuchs Criteria).
Time frame: Entire study: Day 1 of treatment period through 8 week post-treatment follow up visit
Change From Baseline in High Sensitivity CRP
Time frame: Day 29 of the dosing period
Change From Baseline in Blood Neutrophils
Time frame: Day 29 of the dosing period
| Milestone | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| Started | 20 | 20 | 24 | 23 |
| Completed | 16 | 16 | 11 | 15 |
| Not completed | 4 | 4 | 13 | 8 |
Change from Baseline at Day 29 of the dosing period (start of AeroVanc/Placebo administration is considered Day 1 of the dosing period) in the number of MRSA colony forming units (CFU) in sputum culture.
| Log10 CFU/mL | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| Change From Baseline in MRSA Sputum Density. | -0.25 ± 0.181 | -0.30 ± 0.182 | -0.63 ± 0.232 | 0.16 ± 0.201 |
| Log10 CFU/mL | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| Change From Baseline in MRSA Sputum Density. | -0.27 ± 0.208 | -0.28 ± 0.223 | -1.04 ± 0.193 | 0.08 ± 0.200 |
| Log10 CFU/mL | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| Change From Baseline in MRSA Sputum Density. | -0.55 ± 0.259 | 0.09 ± 0.279 | -1.14 ± 0.229 | 0.26 ± 0.216 |
Absolute change from baseline in FEV1 percent predicted
| percentage of predicted FEV1 | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| Change From Baseline in FEV1 | 0.53 ± 1.343 | 1.15 ± 1.356 | -0.68 ± 1.1449 | -2.61 ± 1.314 |
Absolute change from baseline in FVC percent predicted
| percentage of predicted FVC | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| Change From Baseline in FVC | -0.07 ± 1.273 | 1.67 ± 1.283 | -0.47 ± 1.594 | -2.48 ± 1.423 |
Change from Baseline in Cystic Fibrosis Respiratory Symptom Diary (CFRSD) Chronic Respiratory Infection Symptom Scores (CRISS). The minimum score is 0 and the maximum is 100, where a higher score means a worse outcome.
| score on a scale | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| Change From Baseline in Cystic Fibrosis Respiratory Symptom Diary (CFRSD-CRISS) Scores | -6.59 ± 2.620 | -3.02 ± 2.614 | -0.55 ± 2.701 | -5.43 ± 2.552 |
| days | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| Time From Start of Dosing to First Administration of Other Antimicrobial Medications (Oral, Intravenous and/or Inhaled) Due to Respiratory Symptoms. | 69.5 (34.0 to 107.0) | 80.0 (23.0 to NA) | 48.0 (14.0 to 66.0) | NA (43.0 to NA) |
| days | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| Time From Start of Dosing to Exacerbation of Signs/Symptoms (Fuchs Criteria). | 107.0 (13.0 to 107.0) | NA (13.0 to NA) | 49.0 (14.0 to 84.0) | NA (37.0 to NA) |
| mg/dL | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| Change From Baseline in High Sensitivity CRP | -0.34 ± 0.132 | -0.18 ± 0.130 | 0.15 ± 0.223 | -0.09 ± 0.184 |
| 10^9 cells/L | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| Change From Baseline in Blood Neutrophils | 0.20 ± 0.569 | 1.23 ± 0.561 | -0.29 ± 0.557 | 0.04 ± 0.487 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AeroVanc 32 mg | 0/20 (0%) | 4/20 (20%) | 18/20 (90%) |
| Placebo to 32 mg | 0/20 (0%) | 2/20 (10%) | 18/20 (90%) |
| AeroVanc 64 mg | 0/24 (0%) | 1/24 (4.2%) | 20/24 (83.3%) |
| Placebo to 64 mg | 0/23 (0%) | 4/23 (17.4%) | 19/23 (82.6%) |
| Event | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 3/20 | 2/20 | 1/24 | 3/23 |
| HyperglycemiaMetabolism and nutrition disorders | 1/20 | 0/20 | 0/24 | 0/23 |
| PainGeneral disorders | 1/20 | 0/20 | 0/24 | 0/23 |
| Infective exacerbation of bronchiectasisInfections and infestations | 1/20 | 0/20 | 0/24 | 0/23 |
| PneumoniaInfections and infestations | 0/20 | 0/20 | 0/24 | 1/23 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/20 | 0/20 | 0/24 | 1/23 |
| Event | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg |
|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 9/20 | 7/20 | 9/24 | 10/23 |
| Respiratory tract congestionRespiratory, thoracic and mediastinal disorders | 8/20 | 4/20 | 7/24 | 7/23 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 6/20 | 7/20 | 6/24 | 5/23 |
| FatigueGeneral disorders | 5/20 | 4/20 | 8/24 | 3/23 |
| Paranasal sinus hypersecretionRespiratory, thoracic and mediastinal disorders | 6/20 | 3/20 | 4/24 | 1/23 |
| Exercise tolerance decreasedGeneral disorders | 5/20 | 1/20 | 2/24 | 2/23 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 3/20 | 5/20 | 5/24 | 2/23 |
| Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders | 4/20 | 2/20 | 5/24 | 3/23 |
| Forced expiratory volume decreasedInvestigations | 4/20 | 2/20 | 3/24 | 1/23 |
| Weight decreasedInvestigations | 4/20 | 1/20 | 2/24 | 1/23 |
| Age, Categorical(Participants) | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg | Total |
|---|---|---|---|---|---|
| <=18 years | 7 | 6 | 4 | 4 | 21 |
| Between 18 and 65 years | 13 | 14 | 20 | 19 | 66 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg | Total |
|---|---|---|---|---|---|
| Female | 13 | 9 | 9 | 8 | 39 |
| Male | 7 | 11 | 15 | 15 | 48 |
| Region of Enrollment(participants) | AeroVanc 32 mg | Placebo to 32 mg | AeroVanc 64 mg | Placebo to 64 mg | Total |
|---|---|---|---|---|---|
| United States | 20 | 20 | 24 | 23 | 87 |
The record gives a start of Mar 2013, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2020, 5 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Savara Inc.